BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 21452015)

  • 1. Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells.
    Wedel S; Hudak L; Seibel JM; Makarević J; Juengel E; Tsaur I; Wiesner C; Haferkamp A; Blaheta RA
    Clin Exp Metastasis; 2011 Jun; 28(5):479-91. PubMed ID: 21452015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis.
    Wedel S; Hudak L; Seibel JM; Makarević J; Juengel E; Tsaur I; Waaga-Gasser A; Haferkamp A; Blaheta RA
    BMC Cancer; 2011 Aug; 11():375. PubMed ID: 21867506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to the mTOR-inhibitor RAD001 elevates integrin α2- and β1-triggered motility, migration and invasion of prostate cancer cells.
    Tsaur I; Makarević J; Juengel E; Gasser M; Waaga-Gasser AM; Kurosch M; Reiter M; Wedel S; Bartsch G; Haferkamp A; Wiesner C; Blaheta RA
    Br J Cancer; 2012 Aug; 107(5):847-55. PubMed ID: 22782340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells.
    Tsaur I; Hudak L; Makarević J; Juengel E; Mani J; Borgmann H; Gust KM; Schilling D; Bartsch G; Nelson K; Haferkamp A; Blaheta RA
    J Cell Mol Med; 2015 Aug; 19(8):1795-804. PubMed ID: 25808196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion.
    Hudak L; Tezeeh P; Wedel S; Makarević J; Juengel E; Tsaur I; Bartsch G; Wiesner C; Haferkamp A; Blaheta RA
    Prostate; 2012 Dec; 72(16):1719-35. PubMed ID: 22473339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001.
    Wedel S; Hudak L; Seibel JM; Juengel E; Tsaur I; Wiesner C; Haferkamp A; Blaheta RA
    Life Sci; 2011 Feb; 88(9-10):418-24. PubMed ID: 21192952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer.
    Wedel S; Hudak L; Seibel JM; Juengel E; Oppermann E; Haferkamp A; Blaheta RA
    Prostate; 2011 May; 71(7):722-35. PubMed ID: 20954195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-communication between histone H3 and H4 acetylation and Akt-mTOR signalling in prostate cancer cells.
    Makarević J; Tawanaie N; Juengel E; Reiter M; Mani J; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
    J Cell Mol Med; 2014 Jul; 18(7):1460-6. PubMed ID: 24779401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined targeting of the VEGFr/EGFr and the mammalian target of rapamycin (mTOR) signaling pathway delays cell cycle progression and alters adhesion behavior of prostate carcinoma cells.
    Wedel S; Hudak L; Seibel JM; Juengel E; Tsaur I; Haferkamp A; Blaheta RA
    Cancer Lett; 2011 Feb; 301(1):17-28. PubMed ID: 21122981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells.
    Juengel E; Engler J; Natsheh I; Jones J; Mickuckyte A; Hudak L; Jonas D; Blaheta RA
    BMC Cancer; 2009 May; 9():161. PubMed ID: 19473483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells.
    Juengel E; Dauselt A; Makarević J; Wiesner C; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
    Cancer Lett; 2012 Nov; 324(1):83-90. PubMed ID: 22579787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.
    Alshaker H; Wang Q; Kawano Y; Arafat T; Böhler T; Winkler M; Cooper C; Pchejetski D
    Oncotarget; 2016 Dec; 7(49):80943-80956. PubMed ID: 27821815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to the mTOR inhibitor temsirolimus alters adhesion and migration behavior of renal cell carcinoma cells through an integrin α5- and integrin β3-dependent mechanism.
    Juengel E; Makarević J; Reiter M; Mani J; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
    Neoplasia; 2014 Apr; 16(4):291-300. PubMed ID: 24862756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
    Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
    Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma.
    Dong LH; Cheng S; Zheng Z; Wang L; Shen Y; Shen ZX; Chen SJ; Zhao WL
    J Hematol Oncol; 2013 Jul; 6():53. PubMed ID: 23866964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell lines in vitro.
    Juengel E; Engler J; Mickuckyte A; Jones J; Hudak L; Jonas D; Blaheta RA
    BJU Int; 2010 Feb; 105(4):549-57. PubMed ID: 19594733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells.
    Chen CL; Sung J; Cohen M; Chowdhury WH; Sachs MD; Li Y; Lakshmanan Y; Yung BY; Lupold SE; Rodriguez R
    J Pharmacol Exp Ther; 2006 Nov; 319(2):533-42. PubMed ID: 16868035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of adhesion and growth of colon and pancreatic cancer cells by the histone deacetylase inhibitor valproic acid.
    Jones J; Bentas W; Blaheta RA; Makarevic J; Hudak L; Wedel S; Probst M; Jonas D; Juengel E
    Int J Mol Med; 2008 Sep; 22(3):293-9. PubMed ID: 18698487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDAC inhibition suppresses bladder cancer cell adhesion to collagen under flow conditions.
    Juengel E; Meyer dos Santos S; Schneider T; Makarevic J; Hudak L; Bartsch G; Haferkamp A; Wiesner C; Blaheta RA
    Exp Biol Med (Maywood); 2013 Nov; 238(11):1297-304. PubMed ID: 24006305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of histone deacetylase inhibitors on regenerative cell responses in human dental pulp cells.
    Luo Z; Wang Z; He X; Liu N; Liu B; Sun L; Wang J; Ma F; Duncan H; He W; Cooper P
    Int Endod J; 2018 Jul; 51(7):767-778. PubMed ID: 28375564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.